Akebia Therapeutics Inc

Research Akebia Therapeutics Inc (AKBA) on Bullrun: market cap USD 297.77M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAKBA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Market capUSD 297.77M
• Financial periodFY2025
• RevenueUSD 236.20M
• Revenue growth47.5%
• Net income-USD 5.30M
• Free cash flowUSD 67.70M
• Gross margin83.3%

Valuation Snapshot

latest market cap is USD 297.77M.

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients;

Frequently asked questions

What is Akebia Therapeutics Inc's market cap?

Akebia Therapeutics Inc's market capitalization is USD 297.77M.

What does Akebia Therapeutics Inc do?

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.